Skip to main content

Market Overview

Xeris Pharma's Hypoglycemia Med Receives European Nod, Shares Spike

  • The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. Hypoglycemia (low blood sugar level) is a complication of glucose-lowering therapy.
  • Xeris will complete a further administrative step to obtain a license in Great Britain. No re-examination of clinical data by the U.K. regulatory authority is expected.
  • In the U.S., the injection is available under the Gvoke PFS and Gvoke HypoPen brand names, approved in September 2019.
  • Price Action: XERS jumps 17.6% at $7.8 in premarket trading on the last check Friday.

Related Articles (XERS)

View Comments and Join the Discussion!

Posted-In: European Commission hypoglycemiaBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at